View Post

PreludeDx Present Results from PREDICT Study at ASBrS Annual Meeting

In Clinical Trials by Barbara Jacoby

Source: Prelude Corporation From: prnewswire.com Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, presented interim results from its large PREDICT study during a poster presentation (Abstract ID: 581643), titled “Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS”, …

View Post

Continuous chemotherapy improves outcomes and quality of life in advanced breast cancer

In Clinical Trials by Barbara Jacoby

Source: European Society for Medical Oncology From: eurekalert.org Continuous chemotherapy shows greater benefit in patients with advanced breast cancer by both improving survival and maintaining quality of life compared to intermittent scheduling, according to analyses of the Stop&Go study presented at the ESMO Breast Cancer Congress 2019, 2-4 May, Berlin, Germany. (1,2,3) The phase III study randomised 420 patients with …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

Familial breast cancer may be preventable by medication: Austrian experts

In Clinical Trials by Barbara Jacoby

Source: Xinhua From: xinhuanet.com Breast cancer passed down in families may be preventable by the medication Denosumab, which is undergoing a five-year study in Austria. The Austrian Breast and Colorectal Cancer Study Group is leading the work as it examines the drug’s effectiveness on 2,950 patients with a hereditary disposition to this particular form of cancer, according to an Austria …

View Post

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: oaoa.com Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed triple-negative breast …

View Post

Women with breast cancer sought for nationwide weight loss study

In Clinical Trials by Barbara Jacoby

Researchers: Can losing weight prevent recurrence of breast cancer? Beaumont researchers are seeking women with breast cancer for a national research study. Investigators hope to learn if weight loss decreases the likelihood of a recurrence of breast cancer. The research is known as the BWEL study, or Breast Cancer Weight Loss Study. “Previous studies have found that women who are …

View Post

Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** – – Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial – shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute …

View Post

Oak Park Woman Benefits from Clinical Trial for Multiple Myeloma

In Clinical Trials by Barbara Jacoby

By: Elizabeth Katz From: thejewishnews.com Barbara Robins, 75, of Franklin has lived a full life, working as a financial adviser while also keeping herself in optimum health and enjoying her friends, travel and art. Because she’s kept herself so healthy and active, a diagnosis of multiple myeloma in 2015 stopped her in her tracks. “It was completely a surprise,” she …

View Post

Study of tagraxofusp reports 90% response rate for deadly blood cancer with no prior available therapies

In Clinical Trials by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone …

View Post

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

In Clinical Trials by Barbara Jacoby

From: scnow.com Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC). Approximately 20% of patients with TNBC have tumors that highly …